RxSight (NASDAQ:RXST – Get Free Report) and Organigram Global (NASDAQ:OGI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Risk & Volatility
RxSight has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
Profitability
This table compares RxSight and Organigram Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RxSight | -36.80% | -17.35% | -14.70% |
| Organigram Global | 28.14% | -13.39% | -8.67% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RxSight | 3 | 7 | 2 | 0 | 1.92 |
| Organigram Global | 0 | 1 | 2 | 0 | 2.67 |
RxSight presently has a consensus target price of $8.17, indicating a potential upside of 74.62%. Given RxSight’s higher possible upside, equities research analysts clearly believe RxSight is more favorable than Organigram Global.
Valuation & Earnings
This table compares RxSight and Organigram Global”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RxSight | $134.48 million | 1.45 | -$38.94 million | ($1.13) | -4.14 |
| Organigram Global | $309.18 million | 0.43 | -$17.70 million | $0.46 | 2.07 |
Organigram Global has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
78.8% of RxSight shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Organigram Global beats RxSight on 9 of the 13 factors compared between the two stocks.
About RxSight
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
About Organigram Global
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
